NEW YORK, NY / ACCESSWIRE / March 6, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Platinum Pari-Mutuel Holdings Inc. (“Platinum” or the “Company”) (OTC PINK: PPMH) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Platinum securities between July 12, 2016 and February 15, 2017, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/ppmh.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, and failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Platinum’s press releases and financial information lacked validity; (2) Platinum’s disclosure controls and procedures were inadequate; and (3) consequently, Defendants’ public statements were materially false and misleading at all relevant times.

On February 16, 2017, the Securities and Exchange Commission (the SEC) suspended Platinum Pari-Mutuel securities from trading due to questions about the accuracy and adequacy of Platinum’s press releases, since at least July 2016, and the financial information Platinum provided to the public. The SEC specified that those questions regard the valuation of recent corporate acquisitions and forecasts for future revenues.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/ppmh, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Platinum, you have until May 2, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 456638

WINTER PARK, FL / ACCESSWIRE / March 16, 2017 / Imagination TV, Inc. (OTC PINK: IMTV).

To our shareholders,

First, I would like to thank all shareholders for your support. Bringing this company back from the “dead” has been no easy task. There have been many hurdles we have faced and overcome, and more we will face and continue to overcome in the future. I am pleased to report that, as of yesterday, Wednesday, March 15, 2017, we have submitted all the documents required to bring Imagination TV to a status of current, pending OTCMarkets.com review.

We are ready to begin moving to the next phase of Imagination TV’s “re-birth.” We have started to lay the foundation, which will transform Imagination TV into an innovative, revenue and profit producing company, providing longevity, transparency, and shareholder value.

Imagination TV’s business model has always been a combination of technology and entertainment. We will be keeping the core of this business model intact, although we will be heavily incorporating one of the hottest and fastest growing sectors in the market. We fully expect to finalize this new business model within the next 7-10 days, or sooner, and will be releasing a full press release and detailed business plan to the public.

Successfully operating a public company is twofold; there is the business model and successful execution of that business model, and then there is public infrastructure and cap structure. Both elements are extremely important. For this reason, I have begun taking the necessary action to accomplish the following:

Working to restructure the company’s cap structure.
Bringing on a full-time management team.
Adding new board members.
Building a solid asset base.
Beginning to generate revenue.
Remaining transparent with our current and prospective shareholders.
Focusing on building new subsidiaries.

I am of the belief that hard work and smart business will breed success. To that end, I have made it a point to not take a salary from the company, nor do I plan on doing so during this entire transition period. Moving forward, any capital expenditures, albeit for new management, funding options, or any new ventures that the company gets involved with will be directed toward corporate growth, not over-inflated salaries or wasted spending.

Once again, I want to thank everyone for their continued support.

Regards,
Joseph S Sirianni
Imagination TV, Inc.

Safe Harbor for Forward-Looking Statements:

This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities, and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The Company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.

Contact:

Email: info@empireventuresgroup.com
Phone: (307) 201-0602

SOURCE: Imagination TV, Inc.

ReleaseID: 457476

Informing the Pharmaceutical Drug Development, Manufacturing, and Commercialization Industry

CARY, NC / ACCESSWIRE / March 16, 2017 / Industry Standard Research (ISR) today announced the release of its latest CRO market report titled, 2017 Edition of the CRO Market Size Projections: 2016-2021. This report provides readers with a comprehensive assessment of the global market for CRO services. As biopharma companies continue to increase clinical development outsourcing levels, it is imperative for anyone interested in the clinical outsourcing industry to understand how the market is structured.

This report was compiled using secondary, publicly available sources combined with data derived from ISR’s proprietary market research efforts. ISR uses a “top-down” approach to market sizing for the CRO market by looking at overall R&D spending, splitting out the Research from the Development, isolating the Phase I-IV market, and applying the outsourcing percentages gained from ISR’s proprietary market research.

“After several years of producing this report and watching CROs enter and exit the public markets, it is vital to use a methodology that combines both public and proprietary data,” explained Andrew Schafer, President at Industry Standard Research. Schafer continued, “For example, 2015 was a banner year for VC investments into biotech/emerging companies, we saw a strengthening of the preclinical pipeline in 2016; and ISR’s primary research data point towards a continued increase in outsourcing penetration.”

In the report, ISR analyzes and presents the CRO market across various segments, such as: Phase (Phase I, Phase II, Phase III, and Phase IV), Regional geographies, and Service/functional lines (Monitoring, Data Management, etc.). “The past twelve months have been interesting to watch in terms of how Wall Street has treated CROs. For the first time in a while, most of the larger public CROs lagged the DJIA from March 2016 to March 2017, despite delivering some solid top-line growth. From 2016 to 2021, ISR is projecting the CRO market will grow at a 6.8% average annual growth rate,” added Schafer.

For more information on ISR’s 2017 Edition of
the CRO Market Size Projections: 2016-2021 report, please visit ISR’s report page at https://www.isrreports.com/reports/2017-edition-of-the-cro-market-size-projections-2016-2021/.

About Industry Standard Research

Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about ISR’s off-the-shelf intelligence and custom research offerings, please visit the company’s website at www.ISRreports.com, email info@ISRreports.com, or follow ISR on Twitter @ISRreports.

CONTACT:

Andrew Schafer

AndrewS@ISRreports.com

+1 (919) 301-0106

SOURCE: IndustryStandard Research

ReleaseID: 457404

NEW YORK, NY / ACCESSWIRE / March 16, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Kitov Pharmaceutical Holdings LTD (“Kitov” or the “Company”) (NASDAQ: KTOV) and certain of its officers, on behalf of a class who purchased Kitov American Depositary Receipts (“ADRs”) pursuant and/or tradeable to the Company’s initial public offering on or about November 20, 2015 (the “IPO”) and/or on the open market between November 20, 2015 and February 3, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/ktov.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Kitov and its Chief Executive Officer (“CEO”) Isaac Israel published misleading information concerning the conduct of the Company’s clinical trials for its lead drug candidate KIT-302; and (2) consequently, Kitov’s public statements were materially false and misleading at all relevant times.

On February 6, 2017, Calcalist, an Israeli publication, reported that Kitov’s CEO Isaac Israel had been detained and questioned by the Israeli Securities Authority for allegedly publishing misleading information about Kitov’s recent clinical trial. Following this news, Kitov stock dropped $0.33 per share, or 11.46%, to close at $2.55 on February 6, 2017.

On February 7, 2017, the NASDAQ stopped Kitov’s ADRs trading. That same day, Kitov informed investors in a press release, of the ISA’s investigation into its public disclosures regarding KIT-302.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/ktov or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Kitov you have until April 10, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 454672

CRYSTAL RIVER, FL / ACCESSWIRE / March 16, 2017 / B-Scada, Inc. (OTC PINK: SCDA) launched its IoT Platform “Status Device Cloud” in January 2017. The system allows you to develop a cloud based solution for organizing, visualizing, and archiving information from thousands of devices and other sources of data without any programming. The graphics design application makes it easy to create custom screens that display on most modern devices. Entire solutions can be created in hours. The system includes alarms and notifications, reporting, workflow, and a calculation engine for analytics. The entire system is built on the secure and open standard OPCUA (OPC Unified Architecture).

“Since January, we have presented Status Device Cloud to more than 40 companies that are looking for IoT solutions,” says Ron DeSerranno, CEO for B-Scada. “We now have several projects up on the system running beautifully and we are preparing another dozen trial systems for evaluation.”

The type of projects Status Device Cloud is being evaluated for is varied, and the interest is coming from all parts of the globe. Projects include energy management monitoring wind turbines and solar farms, industrial boilers, construction sites and equipment, electricity meters, HVAC (heating, ventilation, and air conditioning equipment), and industrial devices like flow meters. There is also a great deal of interest in using B-Scada wireless sensors with Status Device Cloud for monitoring ovens, freezers, and other equipment in restaurants and convenience stores. Manufacturing companies are looking to remotely monitor their equipment, providing better customer service and support as well as creating new revenue streams for themselves.

“The IoT is poised to explode,” Mr. DeSerranno continues. “50% of the companies that we present our SCADA (Supervisory Control and Data Acquisition) system to indicate that they plan on moving to IoT soon.”

B-Scada has had its SCADA software systems available for several years now. Offering an IoT Platform solution in a SaaS (Software as a Service) model is perfect for the IIoT (Industrial IoT) and places B-Scada in an excellent position to grow.

About B-Scada

B-Scada provides software and hardware solutions for the monitoring and analysis of real time data in the SCADA (Supervisory Control and Data Acquisition), IoT (Internet of Things), and Smart City domains. B-Scada systems are sold worldwide in various verticals, including building automation, transportation, smart grid, manufacturing, agriculture, and commerce. B-Scada’s IoT Platform, “Status Device Cloud,” allows development of complex IoT solutions with connectivity to thousands of different types of devices with no programming. The system is available in a SaaS model or on premise. B-Scada has been recognized as one of the top 20 IoT Solution Providers of 2017 by CIOReview Magazine. Learn more at www.scada.com.

SOURCE: B-Scada, Inc.

ReleaseID: 457474

NEW YORK, NY / ACCESSWIRE / March 16, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Galena Biopharma, Inc. (“Galena” or the “Company”) (NASDAQ: GALE) and certain of its officers, and is on behalf of purchasers of Galena securities from August 11, 2014 through January 31, 2017, inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/gale.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Galena’s sales of Abstral were based on unsustainable sales and marketing practices; (2) such sales and marketing practices could subject Galena to a criminal investigation; and (3) consequently, Galena’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/gale, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Galena, you have until April 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 454993